Home » Posts tagged 'aim'
Tag Archives: aim
#ORPH Open Orphan – Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the completion of its recommended takeover, the Company has appointed Liberum Capital Limited (“Liberum”) as its Nominated Adviser and Joint Broker. Given the timing of the completion of the recommended takeover of Arden Partners Plc, the Exchange has agreed that subject to initial due diligence being undertaken, Liberum has until 5pm on 27 July 2022 to complete its full due diligence.
There can be no guarantee on the outcome of the full due diligence and its impact on Liberum’s decision to continue to act as Nominated Adviser. Accordingly, in such circumstances there is a risk that if the Liberum does not continue to act as Nominated Adviser following completion of its full due diligence and the Company has not found an alternative Nominated Adviser, the Company’s AIM securities may be suspended pursuant to AIM Rule 1. If within one month of that suspension, the Company has failed to appoint a replacement Nominated Adviser, the admission of its AIM securities will be cancelled.
Notwithstanding the extension of time provided in respect of completing full due diligence obligations at engagement, Liberum will continue to be subject to all the ongoing Nominated Adviser responsibilities under the AIM Rules for Nominated Advisers.
finnCap plc and Davy will continue to act as the Company’s Joint Brokers.
Yamin ‘Mo’ Khan, Chief Executive Officer at Open Orphan, said: “As the market is aware, Arden Partners can no longer act as Nomad for listed companies from 29 April 2022 and as such, we thank them for their support over the past number of years. We are delighted to now be working with such a prestigious investment bank as Liberum.”
For further information please contact:
Open Orphan plc |
+353 (0) 1 644 0007 |
||
Cathal Friel, Executive Chairman Yamin Khan, Chief Executive Officer |
|
||
|
|
||
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|
||
|
|
||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
Geoff Nash / James Thompson / Richard Chambers |
|
||
|
|
||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
Anthony Farrell |
|
||
|
|
||
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
||
#TYM Tertiary Minerals – Results of AGM
Tertiary Minerals plc (LON: TYM), the AIM traded mineral exploration and development company, whose focus is on energy transition and precious metals, held its Annual General Meeting (“AGM”) today and is pleased to announce that all resolutions were duly passed.
The following proxy votes were received in respect of the resolutions. Votes withheld are not counted in a poll.
1. Ordinary Resolution: To receive the Accounts and Reports of the Directors and of the Auditors |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
52,675,242 |
99.05 |
505,001 |
0.95 |
0 |
0 |
3,401,793 |
2. Ordinary Resolution: To elect Mr P B Cullen as a director |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
49,641,060 |
89.98 |
4,528,743 |
8.21 |
1,000,000 |
1.81 |
1,412,233 |
3. Ordinary Resolution: To elect Dr M G Armitage as a director |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
49,641,060 |
89.98 |
4,528,743 |
8.21 |
1,000,000 |
1.81 |
1,412,233 |
4. Ordinary Resolution: To reappoint Crowe U.K. LLP as Auditor of the Company |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
51,375,242 |
92.61 |
3,098,639 |
5.59 |
1,000,000 |
1.80 |
1,108,155 |
5. Ordinary Resolution: To authorise the directors to allot shares |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
44,455,976 |
80.15 |
10,013,827 |
18.05 |
1,000,000 |
1.80 |
1,112,233 |
6. Special Resolution: To approve dis-application of pre-emption rights |
||||||
Votes For |
% of votes cast |
Against |
% of votes cast |
At holders’ discretion |
% of votes cast |
No. Withheld |
44,355,976 |
79.97 |
10,113,827 |
18.23 |
1,000,000 |
1.80 |
1,112,233 |
For more information please contact:
Tertiary Minerals plc: |
||
Patrick Cullen, Managing Director |
+44 (0) 1625 838 679 |
|
SP Angel Corporate Finance LLP – Nominated Adviser and Broker |
||
Richard Morrison |
+44 (0) 203 470 0470 |
|
Caroline Rowe |
||
Peterhouse Capital Limited – Joint Broker |
||
Lucy Williams |
+ 44 (0) 207 469 0930 |
|
Duncan Vasey |
||
#POLB Poolbeg Pharma – Shares Spotlight
Take a look at this issue of shares spotlight which features Poolbeg Pharma on page 14-15.
#POLB Poolbeg Pharma – Scientific Advisory Board Appointment
25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board .
Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology and infectious diseases for 32 years. Prof Hoft has published over 140 peer reviewed scientific publications.
Prof Hoft will join the Scientific Advisory Board alongside Dr Elaine Sullivan and Prof Luke O’Neill and with his extensive background in infectious disease, immunology, and vaccinology, will guide the Company on its asset development programmes. Prof Hoft will also work with the Company to scout for prospective in-licencing opportunities.
Prof Hoft is heavily involved in vaccine development research, especially for pandemic influenza and tuberculosis which has seen him undertake pioneering work in T-cell targeting vaccines which is particularly relevant to the Company’s Vaccine Discovery Platform. He is Principal Investigator of the SLU’s Vaccine & Treatment Evaluation Unit (VTEU), one of ten US National Institutes of Health (NIH) centers, placing it among an elite group of top academic centers conducting clinical trials of novel vaccines for global protection against future pandemic challenges. Since the SARS-CoV-2 pandemic the SLU VTEU led by Prof Hoft has featured prominently in the urgent COVID-19 vaccine development and Prof Hoft is the VTEU protocol chair for a first-in-human phase I trial of a novel COVID-19 vaccine. He has received numerous awards from NIH, US Department of Defense, and the Bill & Melinda Gates Foundation and is a regular advisor to the World Health Organisation.
Read Prof Hoft’s full bio on Poolbeg’s website .
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “Prof Hoft is a great addition to the Poolbeg Scientific Advisory Board, joining Dr Elaine Sullivan and Prof Luke O’Neill. His expertise in infectious disease, particularly with severe influenza and vaccine development will be invaluable as we develop Poolbeg’s pipeline of assets. He will also work with the Company to scout for prospective assets to in-licence and develop. Prof Hoft is a widely respected specialist within our industry and we look forward to working with him as we continue our growth journey.”
Prof Daniel Hoft, M.D., Ph.D., commented:
“Poolbeg has an interesting portfolio of assets within infectious disease with an exciting lead asset, POLB 001. Coupled with its unique access to 20 years’ of human viral challenge study data, means its approach has real potential in this space. I look forward to helping support the business as it develops.”
– Ends –
Enquiries
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+353 (0) 1 644 0007 |
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM)
|
+44 (0) 20 7220 0500 |
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 |
#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development
18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.
The Company intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in the molecule’s development. To enable this study, the Company has signed a Letter of Intent to retain the Centre for Human Drug Research (CHDR) to run the challenge study and signed an agreement with SEDA Pharmaceutical Development Services for drug formulation services. A vendor has also been selected for GMP* manufacturing of POLB 001.
In this study, clinical researchers from CHDR will stimulate a healthy volunteer’s immune system with bacterial lipopolysaccharide (LPS) in a safe and controlled clinical environment. The study will provide key human data on the efficacy of POLB 001 in dampening the immune response in otherwise healthy volunteers. It will use LPS to simulate the effects of treating severe influenza in the volunteers without the virus itself being present. In cases of severe influenza, the body produces an over-heightened immune response that can cause more damage to the body than the virus itself. POLB 001’s mode of action is to reduce this hyper-immune response. The design of the study (the study protocol) is expected to be finalised by the end of Q1 2022.
In advance of the Phase Ib study commencing, the Company has completed the manufacturing of a non-GMP* batch of POLB 001 which is on hand for any non-clinical (not administered to humans) requirements, such as formulation. This is also an important step in validating the manufacturing process. On this basis, manufacturing can now be scaled up as required as the clinical development phase progresses. The Company will now move towards manufacturing GMP* grade POLB 001 material needed for the LPS challenge study and has similarly selected a vendor for this work.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:
“We are delighted to be progressing our POLB 001 asset as planned, with preparatory steps in motion in advance of the LPS human challenge study clinical trial. We have selected experienced partners in SEDA to formulate the product, and CHDR to run our LPS human challenge study. The clinical study is expected to commence in June 2022, as detailed at IPO. With our capital light and early monetisation model, we are actively developing infectious disease assets with modest investment where they can be monetised / licenced to Big Pharma. We will continue to provide updates as we progress the programme.”
*Good Manufacturing Practice (GMP) is the regulatory code of standards that a medicine’s manufacturer must meet in its production processes to enable administration to humans.
Enquiries
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO |
+353 (0) 1 644 0007 |
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM) |
+44 (0) 20 7220 0500 |
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell |
+44 (0) 207 614 5900 |
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist |
+353 (0) 1 679 6363 |
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 poolbeg@instinctif.com |
#ORPH Open Orphan – £1.5m Contract renewal for Venn Life Sciences
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years.
The renewed contract will commence in January 2022, with the Venn team in Breda providing dedicated clinical pharmacokinetics (‘PK’) support to this leading global pharmaceutical client on an array of drug development programmes, to study the absorption, distribution, metabolism and excretion of drugs within the body.
Venn, which has been a part of Open Orphan since 2019, offers a combination of drug development consultancy, clinical trial design and execution. These combined services enable Venn to provide its clients with a complete end-to-end service on all the stages of their drug development programmes, from the early planning phase to final execution. Venn has offices in Breda (Netherlands) and Paris (France).
Cathal Friel, Executive Chairman of Open Orphan, said: “We are delighted to see this contract renewal signed by the Venn team in Breda with a client that it has been working with since 2012. The continued support by Venn to a distinguished partner such as this demonstrates the value of Venn’s clinical pharmacokinetics offering, as part of its comprehensive offering in drug development consultancy, clinical trial design and execution.
“Open Orphan’s strengths lie in the established relationships we have with our pharmaceutical partners and we expect to continue to develop these relationships as well as focusing on converting our existing pipeline of new business opportunities.”
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
For further information please contact:
Open Orphan plc |
+353 (0) 1 644 0007 |
|||
Cathal Friel, Executive Chairman |
|
|||
|
|
|||
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0) 20 7614 5900 |
|||
John Llewellyn-Lloyd / Louisa Waddell |
|
|||
|
|
|||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
|||
Geoff Nash / James Thompson/ Richard Chambers |
|
|||
|
|
|||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
|||
Anthony Farrell |
|
|||
|
|
|||
Walbrook PR (Financial PR & IR) |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com |
|||
Paul McManus/ Sam Allen/ Louis Ashe-Jepson |
+44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |